Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)
- Conditions
- Cardiovascular Prevention Behaviour
- Registration Number
- NCT04361877
- Lead Sponsor
- LMU Klinikum
- Brief Summary
The study aims to determine the impact of COVID-19 pandemic lockdown on cardiovascular prevention behaviour.
- Detailed Description
The COVID-19 pandemic resulted in a lockdown and social distancing in most countries all over the world. The impact of this national intervention on cardiovascular prevention behaviour (physical exercise, nutrition, smoking) is unknown. The COLA Trial aims to help clarifying these questions.
An online survey was distributed among bavarian students with standardized questions about physical activity, nutritional behavior, smoking and alcohol intake before and during lockdown.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1900
healthy adults over 18 years
any condition that does not allow physical activity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of physical activity 14 days Questionnaire, 3 level scale ranging from less activity (Level 1), unchanged activity (Level 2), to increased activity (Level 3)
- Secondary Outcome Measures
Name Time Method step count 6 days wearables
change of stress level 14 days Questionnaire, 3 level scale ranging from lower stress level (Level 1), unchanged stress level (Level 2), to increased stress level (Level 3)
semiquantitative change of alcohol intake 14 days Questionnaire, 3 level scale ranging from less alcohol intake (Level 1), unchanged alcohol intake (Level 2), to increased alcohol intake (Level 3)
change of smoking behaviour 14 days Questionnaire, 3 level scale ranging from less smoking(Level 1), unchanged smoking (Level 2), to increased smoking (Level 3)
change of nutrition behaviour 14 days Questionnaire, 3 level scale ranging from less food intake (Level 1), unchanged food intake (Level 2), to increased food intake (Level 3)
Trial Locations
- Locations (1)
University Hospital Munich (LMU Klinikum)
🇩🇪Munich, Germany